Results 161 to 170 of about 838,442 (361)
Advanced Science, EarlyView.Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan +6 more
wiley +1 more source
, 2017 Let-7a-3 transcribes the miRNA let-7a, of which the expression is dysregulated in cancer. We evaluated the significance of let-7a-3 gene methylation in patients with de novo acute myeloid leukemia (AML).
Ko, Ya-Chen;Fang, Woei-Horng;Lin, Tsung-Chin;Hou, Hsin-An;Chen, Chien-Yuan;Tien, Hwei-Fang;Lin, Liang-In +1 more
core +1 more source
Therapy of Acute Myeloid Leukemia
Cancer Control, 2001 The Eastern Cooperative Oncology Group (ECOG) has recently reviewed the outcome for more than 1,400 patients with previously untreated AML entered on five successive clinical trials.5,6 Each trial included daunorubicin and cytarabine for induction.
openaire +2 more sources
Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies
Advanced Science, EarlyView.In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang +4 more
wiley +1 more source
Proto-oncogene c-jun expression is induced by AML1-ETO in a JNK dependent manner:possible role in the pathogenesis of acute myeloid leukemia [PDF]
, 2003 Overexpression of proto-oncogene c-jun and constitutive activation of the Jun NH2-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process.
Elsaesser, Annika
core
Advances in Cancer Immunotherapy for Solid Tumors
Advanced Science, EarlyView.Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz +1 more
wiley +1 more source
High-Resolution Genome-Wide Single Nucleotide Polymorphism Mapping in Acute Myeloid Leukaemia
, 2008 PhDInvestigation of the genetics of acute myeloid leukaemia (AML) has revealed the underlying basis of the disease and led to targets for therapy. High-resolution single nucleotide polymorphism (SNP) arrays detected regions of loss of heterozygosity ...
Raghavan, Manoj
core
Advanced Intelligent Discovery, EarlyView.scTIGER2.0 is a deep‐learning framework that infers gene regulatory networks from single‐cell RNA sequencing data. By integrating correlation, pseudotime ordering, deep learning and bootstrap‐based significance testing, it reduces false positives and reveals directional gene interactions.
Nishi Gupta +3 more
wiley +1 more source
Cell Death and DiseaseThis study explores innovative therapeutic approaches for acute myeloid leukemia by examining the synergistic effects of the histone deacetylase inhibitor chidamide in combination with cytarabine. In both in vitro and in vivo models, the drug combination
Qing Li +13 more
doaj +1 more source
, 2004 The granulocyte-macrophage colony-stimulating factor (GM-CSF) analog E21R binds to the GM-CSF receptor complex with low affinity and acts as a competitive antagonist.
Jakupovic, I. +3 more
core